Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma; Small Intestine Cancer
MeSH terms: Lymphoma; Intestinal Neoplasms
Study type: Observational

Summary: 
      RATIONALE: Measuring the number of radiolabeled white blood cells in non-Hodgkin's lymphoma
      tumors may help doctors predict how well patients will respond to treatment, and may help the
      study of cancer in the future.

      PURPOSE: This study is measuring radiolabeled white blood cells in patients with
      non-Hodgkin's lymphoma.
    

Detailed description: 
      OBJECTIVES:

        -  Determine the number of indium In 111-labeled peripheral blood mononuclear cells (PBMCs)
           and indium In 111-labeled polymorphonuclear leukocytes (PMNLs) trafficking into lymphoma
           tumors prior to therapy in patients with non-Hodgkin's lymphoma.

        -  Compare the number of PBMC and PMNL trafficking prior to vs after therapy in these
           patients.

        -  Compare, preliminarily, the number of in vivo baseline (i.e., pre-therapy) trafficking
           of PBMCs vs PMNLs in these patients.

        -  Gather important data regarding the inter- and intra-patient variability of effector
           cell trafficking into these tumors.

        -  Assess the relationship between response at 8-12 weeks and the magnitude of baseline
           effector cell trafficking or the magnitude of post-rituximab effector cell trafficking
           in these patients.

      OUTLINE: This is a multicenter study. Patients are assigned to 1 of 2 groups.

        -  Group I: Patients receive autologous indium In 111 (^111In)-labeled peripheral blood
           mononuclear cells on day 0.

        -  Group II: Patients receive autologous ^111In-labeled polymorphonuclear leukocytes on day
           0.

      In both groups, patients undergo blood collection on day 0. Patients then undergo full-body
      single-photon emission-computed tomography (SPECT) scan 4 hours after cell infusion and on
      day 2. The labeling and imaging process may be repeated after at least 1 course of anticancer
      treatment.

      Cellular uptake is measured by reader/visual interpretation, a semiquantitative grading
      system, and tumor-to-background uptake ratios.

      PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
    

Intervention name(s): radionuclide imaging; indium In 111-labeled autologous peripheral blood mononuclear cells; indium In 111-labeled autologous polymorphonuclear leukocytes
Intervention type(s): Procedure; Radiation; Radiation
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        community sample
      
Keywords: AIDS-related peripheral/systemic lymphoma; AIDS-related primary CNS lymphoma; anaplastic large cell lymphoma; angioimmunoblastic T-cell lymphoma; extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue; intraocular lymphoma; nodal marginal zone B-cell lymphoma; primary central nervous system non-Hodgkin lymphoma; recurrent adult Burkitt lymphoma; recurrent adult diffuse large cell lymphoma; recurrent adult diffuse mixed cell lymphoma; recurrent adult diffuse small cleaved cell lymphoma; recurrent adult immunoblastic large cell lymphoma; recurrent adult lymphoblastic lymphoma; recurrent adult T-cell leukemia/lymphoma; recurrent cutaneous T-cell non-Hodgkin lymphoma; recurrent grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma; recurrent grade 3 follicular lymphoma; recurrent mantle cell lymphoma; recurrent marginal zone lymphoma; recurrent mycosis fungoides/Sezary syndrome; recurrent small lymphocytic lymphoma; small intestine lymphoma; splenic marginal zone lymphoma; stage III adult Burkitt lymphoma; stage III adult diffuse large cell lymphoma; stage III adult diffuse mixed cell lymphoma; stage III adult diffuse small cleaved cell lymphoma; stage III adult immunoblastic large cell lymphoma; stage III adult lymphoblastic lymphoma; stage III adult T-cell leukemia/lymphoma; stage III cutaneous T-cell non-Hodgkin lymphoma; stage III grade 1 follicular lymphoma; stage III grade 2 follicular lymphoma; stage III grade 3 follicular lymphoma; stage III mantle cell lymphoma; stage III marginal zone lymphoma; stage III mycosis fungoides/Sezary syndrome; stage III small lymphocytic lymphoma; stage IV adult Burkitt lymphoma; stage IV adult diffuse large cell lymphoma; stage IV adult diffuse mixed cell lymphoma; stage IV adult diffuse small cleaved cell lymphoma; stage IV adult immunoblastic large cell lymphoma; stage IV adult lymphoblastic lymphoma; stage IV adult T-cell leukemia/lymphoma; stage IV cutaneous T-cell non-Hodgkin lymphoma; stage IV grade 1 follicular lymphoma; stage IV grade 2 follicular lymphoma; stage IV grade 3 follicular lymphoma; stage IV mantle cell lymphoma; stage IV marginal zone lymphoma; stage IV mycosis fungoides/Sezary syndrome; stage IV small lymphocytic lymphoma; Waldenström macroglobulinemia; stage I adult Burkitt lymphoma; stage I adult diffuse large cell lymphoma; stage I adult diffuse mixed cell lymphoma; stage I adult diffuse small cleaved cell lymphoma; stage I adult immunoblastic large cell lymphoma; stage I adult lymphoblastic lymphoma; stage I adult T-cell leukemia/lymphoma; stage I cutaneous T-cell non-Hodgkin lymphoma; stage I grade 1 follicular lymphoma; stage I grade 2 follicular lymphoma; stage I grade 3 follicular lymphoma; stage I mantle cell lymphoma; stage I marginal zone lymphoma; stage I small lymphocytic lymphoma; stage II adult T-cell leukemia/lymphoma; adult grade III lymphomatoid granulomatosis; adult nasal type extranodal NK/T-cell lymphoma; recurrent adult grade III lymphomatoid granulomatosis; contiguous stage II adult Burkitt lymphoma; contiguous stage II adult diffuse large cell lymphoma; contiguous stage II adult diffuse mixed cell lymphoma; contiguous stage II adult diffuse small cleaved cell lymphoma; contiguous stage II adult immunoblastic large cell lymphoma; contiguous stage II adult lymphoblastic lymphoma; contiguous stage II grade 1 follicular lymphoma; contiguous stage II grade 2 follicular lymphoma; contiguous stage II grade 3 follicular lymphoma; contiguous stage II mantle cell lymphoma; contiguous stage II marginal zone lymphoma; contiguous stage II small lymphocytic lymphoma; noncontiguous stage II adult Burkitt lymphoma; noncontiguous stage II adult diffuse large cell lymphoma; noncontiguous stage II adult diffuse mixed cell lymphoma; noncontiguous stage II adult diffuse small cleaved cell lymphoma; noncontiguous stage II adult immunoblastic large cell lymphoma; noncontiguous stage II adult lymphoblastic lymphoma; noncontiguous stage II grade 1 follicular lymphoma; noncontiguous stage II grade 2 follicular lymphoma; noncontiguous stage II grade 3 follicular lymphoma; noncontiguous stage II mantle cell lymphoma; noncontiguous stage II marginal zone lymphoma; noncontiguous stage II small lymphocytic lymphoma; stage I mycosis fungoides/Sezary syndrome; stage II mycosis fungoides/Sezary syndrome; stage II cutaneous T-cell non-Hodgkin lymphoma